Dissolution of gallstones--when and how?
Availability of bile acid therapy for gallstone dissolution adds another therapeutic choice for treatment of gallstone disease. Because dissolution is slow and eventual outcome uncertain, surgery remains the treatment of choice for most patients who have experienced symptoms clearly related to their gallstones. Patients with only dyspeptic or no gastrointestinal symptoms, especially if significant associated cardiac or pulmonary disease exists, may be candidates for bile acid therapy with chenodeoxycholic acid or its 7-beta epimer, ursodeoxycholic acid, when available. Fifty to 75 per cent of patients, depending on individual criteria, may anticipate complete dissolution. Radiolucent gallstones and gallbladder opacification are basic requirements for cholelitholytic therapy. Periodic assessment of laboratory parameters is necessary at routine visits and when unexpected symptoms occur. In a few patients, evidence of obstructive gallstone disease will develop during bile acid therapy and surgery will be required. The value of bild acid therapy for the relief of dyspeptic symptoms, the role of bile analysis, and optimal long-term therapy remain to be established.
D001646:Bile / Q000032:analysis; D002635:Chenodeoxycholic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D002765:Cholecystography; D002769:Cholelithiasis / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008107:Liver Diseases / Q000150:complications; D009765:Obesity / Q000150:complications; D011247:Pregnancy; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use
D002635:Chenodeoxycholic Acid; D014580:Ursodeoxycholic Acid